Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals.
Strupp C, Gattermann N, Giagounidis A, Aul C, Hildebrandt B, Haas R, Germing U.
Leuk Res. 2003 May;27(5):397-404. doi: 10.1016/s0145-2126(02)00220-5.
Refractory anemia with excess of blasts: increased survival when treated with cyclophosphamide, methotrexate and 6-mercaptopurine.
Majluf-Cruz A, Hurtado R, Vargas-Vorackova F, Labardini-Méndez J.
Eur J Haematol. 1999 Apr;62(4):213-8. doi: 10.1111/j.1600-0609.1999.tb01749.x.
Biological characterization of refractory anemia with excess of blasts.
Maiolo AT, Foa P, Pagetti D, Baldini L, Mozzana R, Ortolani S, Colantoni A, Lombardi L, Lavezzi AM, Polli EE.
Haematologica. 1987 Nov-Dec;72(6 Suppl):126-9.
Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
Salim O, Toptas T, Avsar E, Yucel OK, Ozturk E, Ferhanoglu B, Geduk A, Mehtap O, Tombak A, Tiftik EN, Deveci B, Kurtoglu E, Kara O, Atagunduz IK, Tuglular TF, Undar L.
Leuk Res. 2016 Jun;45:82-9. doi: 10.1016/j.leukres.2016.04.003. Epub 2016 Apr 11.
Re-evaluation of refractory anemia with excess blasts in transformation.
Ohyashiki K, Nishimaki J, Shoji N, Miyazawa K, Kimura Y, Ohyashiki JH.
Leuk Res. 2001 Nov;25(11):933-9. doi: 10.1016/s0145-2126(01)00054-6.
Refractory anemia with excess of blasts in transformation. Clinical, hematologic, and cytogenetic findings in nine patients.
Smadja N, Krulik M, de Gramont A, Gonzalez-Canali G, Audebert AA, Debray J.
Cancer Genet Cytogenet. 1989 Oct 1;42(1):55-65. doi: 10.1016/0165-4608(89)90008-3.
Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study.
Kikuchi A, Hasegawa D, Ohtsuka Y, Hamamoto K, Kojima S, Okamura J, Nakahata T, Manabe A; Japanese Paediatric Myelodysplastic Syndrome (MDS) Study Group.
Br J Haematol. 2012 Sep;158(5):657-61. doi: 10.1111/j.1365-2141.2012.09210.x. Epub 2012 Jun 26.
Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
Wei J, Zhou XF, Zhao F, Zhou JF, Chen Y.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb;17(1):111-6.
Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.
Moon JH, Lee SJ, Lee YJ, Kang BW, Chae YS, Kim JG, Suh JS, Sohn SK.
Ann Hematol. 2012 Mar;91(3):367-73. doi: 10.1007/s00277-011-1321-1. Epub 2011 Sep 27.
Re-analysis of prognosis in refractory anemia alone, with ring sideroblasts, and with excess of blasts.
Oguma S, Yoshida Y, Uchino H, Okuma M, Maekawa T, Nomura T.
Int J Hematol. 1993 Jan;57(1):15-25.
